Download PDF
Krankenhaushygiene up2date 2016; 11(02): 155-165
DOI: 10.1055/s-0042-107365
Nosokomiale Infektionen
© Georg Thieme Verlag KG Stuttgart · New York

Fäkaler Mikrobiomtransfer bei Clostridium-difficile-Infektion

Philipp Ehlermann
Further Information

Publication History

Publication Date:
10 June 2016 (online)

Also available at
    Permissions and Reprints All articles of this category
Kernaussagen

  • Der fäkale Mikrobiomtransfer ist eine erfolgsversprechende Option bei rezidivierender Clostridium-difficile-Infektion.

  • Im Gegensatz zur hohen Akzeptanz der Methode bei Patienten und in der Öffentlichkeit, besteht eine deutlich niedrigere Akzeptanz bei Ärzten.

  • Ein FMT ist einfach durchführbar und hat eine gute Verträglichkeit.

  • Mit der Entwicklung von Enterokapseln für den FMT könnte die Diskussion über einen antegraden oder retrograden Transfer in den Hintergrund treten, sobald hierzu weitere randomisierte Studien vorliegen und die rechtlichen Anforderungen an den Herstellungsprozess geklärt sind.

  • Weitere offene Fragen sind der Nutzen einer zusätzlichen Darmreinigung sowie die Vermeidung einer Protonenpumpentherapie als Risikofaktor für ein erneutes Rezidiv.

 

  • Literatur

  • 1 Sender R, Fuchs S, Milo R. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. Cell 2016; 164: 337-340
    CrossrefPubMedGoogle Scholar
  • 2 Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection?. Clin Microbiol Infect 2012; 18 (Suppl. 06) 21-S27
    Google Scholar
  • 3 Tartof SY, Rieg GK, Wei R et al. A Comprehensive Assessment Across the Healthcare Continuum: Risk of Hospital-Associated Clostridium difficile Infection Due to Outpatient and Inpatient Antibiotic Exposure. Infect Control Hosp Epidemiol 2015; 36: 1409-1416
    CrossrefPubMedGoogle Scholar
  • 4 Zhang F, Luo W, Shi Y et al. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am J Gastroenterol 2012; 107: 1755-1756
    Google Scholar
  • 5 Borody TJ, Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol Clin North Am 2012; 41: 781-803
    CrossrefGoogle Scholar
  • 6 van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-414
    CrossrefPubMedGoogle Scholar
  • 7 Buffie CG, Bucci V, Stein RR et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015; 517: 205-208
    CrossrefGoogle Scholar
  • 8 Weingarden AR, Chen C, Bobr A et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 2014; 306: G310-319
    CrossrefPubMedGoogle Scholar
  • 9 Weingarden AR, Chen C, Zhang N et al. Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection. J Clin Gastroenterol 2015; Epub ahead of print
    Google Scholar
  • 10 Surawicz CM. Treatment of recurrent Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 32-38
    Google Scholar
  • 11 Agrawal M, Aroniadis OC, Brandt LJ et al. The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. J Clin Gastroenterol 2016; 50: 403-407
    Google Scholar
  • 12 Li YT, Cai HF, Wang ZH et al. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther 2016; 43: 445-457
    CrossrefGoogle Scholar
  • 13 Lübbert C, John E, von Müller L. Clostridium difficile infection: guideline-based diagnosis and treatment. Dtsch Arztebl Int 2014; 111: 723-731
    Google Scholar
  • 14 Lee CH, Steiner T, Petrof EO et al. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA 2016; 315: 142-149
    CrossrefPubMedGoogle Scholar
  • 15 Youngster I, Russell GH, Pindar C et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014; 312: 1772-1778
    CrossrefPubMedGoogle Scholar
  • 16 Hirsch BE, Saraiya N, Poeth K et al. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis 2015; 15: 191
    CrossrefGoogle Scholar
  • 17 Tian H, Ding C, Gong J et al. Freeze-dried, Capsulized Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection. J Clin Gastroenterol 2015; 49: 537-538
    Google Scholar
  • 18 Bowman KA, Broussard EK, Surawicz CM. Fecal microbiota transplantation: current clinical efficacy and future prospects. Clin Exp Gastroenterol 2015; 8: 285-291
    CrossrefGoogle Scholar